Alpha-actinin-4 as an oncogenic driver and therapeutic target in melanoma

尽管最近在靶向治疗和免疫治疗方面取得了进展，但转移性黑色素瘤的根治性治疗仍然是一个尚未解决的健康问题。在这个项目中，我们可能会证明一种名为ACTN4的蛋白质在黑色素瘤细胞中高水平异常表达，并在黑色素瘤细胞的生存和耐药中发挥重要作用，从而确定单独或与其他药物联合抑制ACTN4是治疗黑色素瘤的一种新方法。

Despite the recent advances in targeted therapy and immunotherapy, curative treatment of metastatic melanoma remains an unmet health problem. In this project, we will potentially demonstrate that a protein called ACTN4 is abnormally expressed at high levels in melanoma cells and plays an important role for melanoma cell survival and resistance to treatment, and thus identify inhibition of ACTN4, either alone or in combination with other drugs, as a novel approach in the treatment of melanoma.